Effects of Phytosterol Supplementation on Serum Levels of Lipid Profiles,Liver Enzymes,Inflammatory Markers,Adiponectin, and Leptin in Patients Affected by Nonalcoholic Fatty Liver Disease: A Double-Blind,Placebo-Controlled,Randomized Clinical Trial

ABSTRACT

Objective: Considering the high prevalence of nonalcoholic fatty liver disease and based on the evidence about the role of dietary cholesterol in liver inflammation, and also with regard to the effect of phytosterols on the metabolism of cholesterol, we aimed at exploring the therapeutic potential of phytosterol supplementation against nonalcoholic fatty liver disease.

Method: Thirty-eight patients with nonalcoholic fatty liver disease were randomly divided into two groups: The phytosterol group (n = 19) received a 1.6-g phytosterol supplement daily and the control group (n = 19) received 1.6 g starch daily as placebo for an 8-week period. Blood samples of all patients were taken at baseline (week 0) and at the end of the study (week 8) for measurement of lipid profiles, liver enzymes, inflammatory markers, adiponectin, and leptin.

Results: Phytosterol supplementation significantly improved the levels of low-density lipoprotein cholesterol, aspartate aminotransferase, alanine aminotransferase, and tumor necrosis factor alpha compared to the placebo group. On the other hand, there were no significant differences between the two groups in total cholesterol, triglycerides, high-density lipoprotein cholesterol, very-low-density lipoprotein cholesterol, ratios of low-density lipoprotein cholesterol/high-density lipoprotein cholesterol and total cholesterol/high-density lipoprotein cholesterol, gamma-glutamyl transferase, interleukin 6, high-sensitivity C-reactive protein, adiponectin, and leptin.

Conclusions: The present study suggested that daily consumption of 1.6 g phytosterols efficiently lowers low-density lipoprotein cholesterol, aspartate aminotransferase, alanine aminotransferase, and tumor necrosis factor alpha in patients with nonalcoholic fatty liver disease.     

Effect of Soy Milk on Metabolic Status of Patients with Nonalcoholic Fatty Liver Disease: A Randomized Clinical Trial

Objective: Studies in experimental models of nonalcoholic fatty liver disease (NAFLD) have reported positive effects of soy components in improving metabolic parameters. Whether such effects could be achieved through consumption of whole soy foods in patients with NAFLD is still unclear. Therefore, this trial was conducted to assess the effects of soy milk on metabolic parameters of patients with NAFLD.

Methods: This parallel randomized clinical trial was conducted on 70 patients with NAFLD. Patients in the soy milk group consumed 240?ml of soy milk daily as a part of low-calorie diet (i.e., 500-deficit calorie diet) for 8?weeks. Patients in the control group just followed the low-calorie diet. Grade of fatty liver, liver enzymes, lipid profile, serum high-sensitivity C-reactive protein (hs-CRP), and anthropometric indices were measured at baseline and the end of the trial.

Results: At the end of the trial, the soy milk group had significantly higher reduction in serum alanine aminotransferase (ALT) (–12.06?±?17.61?IU/L in the soy milk group versus –5?±?8.58?IU/L in the control group, p?=?0.04) and hs-CRP (–1.32?±?1.60?mg/L in the soy milk group versus –0.36?±?1.54?mg/L in the control group, p?=?0.01) compared to the control group. However, changes in fatty liver grade and other liver enzymes, including aspartate aminotransferase, alkaline phosphatase, and gamma-glutamyl transferase, as well as lipid profile and anthropometric indices were not significantly different between the treatment groups.

Conclusion: Consumption of soy milk in the context of a restricted-calorie diet for 8?weeks had favorable effects on serum ALT and hs-CRP in patients with NAFLD.     

Functions of Coenzyme Q10 Supplementation on Liver Enzymes,Markers of Systemic Inflammation,and Adipokines in Patients Affected by Nonalcoholic Fatty Liver Disease: A Double-Blind,Placebo-Controlled,Randomized Clinical Trial

Background: Nonalcoholic fatty liver disease (NAFLD) is a chronic liver disorder related to inflammation. Coenzyme Q10 (CoQ10) is a natural compound that has recently been considered as an anti-inflammatory factor. In the current study we aimed to evaluate the effects of CoQ10 supplementation on liver enzymes, inflammation status, and adipokines in patients with NAFLD.

Methods: Forty-one subjects with NAFLD participated in the current randomized, double-blind, placebo-controlled trial. The participants were randomly divided into 2 groups: one group received CoQ10 capsules (100 mg once a day) and the other received placebo for 12 weeks. Blood samples of each patient were taken before and after the 12-week intervention period for measurement of liver aminotransferases, inflammatory biomarkers, and adipokines (adiponectin and leptin).

Results: Taking 100 mg CoQ10 supplement daily resulted in a significant decrease in liver aminotransferases (aspartate aminotransferase [AST] and gamma-glutamyl transpeptidase [GGT]), high-sensitivity C-reactive protein (hs-CRP), tumor necrosis factor α, and the grades of NAFLD in the CoQ10 group in comparison to the control group (p < 0.05). In addition, patients who received CoQ10 supplement had higher serum levels of adiponectin (p = 0.016) and considerable changes in serum leptin (p = 0.053). However, no significant changes occurred in serum levels of interleukin-6 in both groups.

Conclusion: The present study suggested that CoQ10 supplement at a dosage of 100 mg could be effective for improving the systemic inflammation and biochemical variables in NAFLD.     

Comparison of Calorie-Restricted Diet and Resveratrol Supplementation on Anthropometric Indices,Metabolic Parameters,and Serum Sirtuin-1 Levels in Patients With Nonalcoholic Fatty Liver Disease: A Randomized Controlled Clinical Trial

Objective: There is a promising perspective regarding the potential effect of resveratrol in preventing and treating metabolic disturbances similar to that of calorie restriction. The aim of this study was to evaluate the effects of calorie-restricted (CR) diet on metabolic parameters and then to investigate whether resveratrol supplementation has beneficial effects similar to CR diet in patients with nonalcoholic fatty liver disease (NAFLD).

Methods: This randomized controlled clinical trial was conducted in 90 patients with NAFLD (males and females) aged 20 to 60 years with body mass index (BMI) ranging from 25 to 35 kg/m². Participants were assigned to one of three intervention groups as follows: The CR diet group (n = 30) received a prescribed low-calorie diet, the resveratrol group (n = 30) received 600 mg pure trans-resveratrol (2 × 300 mg) daily, and the placebo group (n = 30) received placebo capsules (2 × 300 mg) daily for 12 weeks. Fasting blood samples, anthropometric measurements, and dietary intake and physical activity data were collected for all participants at baseline and at the end of the trial.

Results: CR diet significantly reduced weight (by 4.5%); BMI; waist circumference; waist-to-hip ratio; and serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), and lipid profiles in participants compared to resveratrol and placebo (all p < 0.05). Significant reductions in weight (by 1.1%) and BMI were found in the resveratrol group compared to the placebo group (p < 0.05). ALT, AST, and lipid profiles did not change significantly in the resveratrol group (all p > 0.05). No significant changes were seen in hepatic steatosis grade, serum glycemic parameters, and high-density lipoprotein cholesterol and sirtuin-1 levels in any group (all p > 0.05).

Conclusions: CR diet with moderate weight loss has favorable effects on NAFLD, and resveratrol supplementation induced weight loss but failed to mimic other aspects of CR diet. Future studies are warranted to evaluate the long-term and dose-dependent effects of resveratrol on metabolic diseases.     

血清铁蛋自在非酒精性脂肪性肝病中的临床意义

目的探讨血清铁蛋白（sF）水平在成人非酒精性脂肪性肝病（NAFLD）患者中的临床意义。方法对入选的158例健康体检人群,进行血清铁蛋白、总胆固醇（TC）、甘油三酯（TG）、高密度脂蛋白（HDL—C）、低密度脂蛋白（LDL—C）、空腹血糖（FBG）、血尿酸（UA）、谷草转氨酶（AST）及谷丙转氨酶（ALT）等各指标检测及肝脏超声检查,根据肝脏超声结果分为NAFLD组（68例）及正常对照组（90例）,比较两组间血清铁蛋白水平及血脂、血糖、尿酸、转氨酶等生化指标情况。结果NAFLD组中血清铁蛋白水平及甘油三酯、尿酸、转氨酶明显高于对照组,而高密度脂蛋白明显低于对照组（p〈0．01）;进一步相关性分析显示．血清铁蛋白与谷草转氨酶及谷丙转氨酶显著相关（r=0．260、0．299,P〈0．01）。结论血清铁蛋白水平的升高可能提示NAFLD患者肝损的一个有效指标,并在NAFLD的进展过程中可能起一定的作用。     

Effects of Probiotic Supplementation on Oxidative Stress Indices in Women with Rheumatoid Arthritis: A Randomized Double-Blind Clinical Trial

Objective: Rheumatoid arthritis (RA) is an autoimmune inflammatory disease that causes great pain and disability and increasing oxidative stress in patients. The objective of the present study was to evaluate the effects of probiotics—live microorganisms with many health benefits, including antioxidant properties—on oxidative stress indices of patients with RA. This study is a secondary analysis from a previously published study

Methods: In a randomized double-blind placebo-controlled clinical trial, 46 patients with RA were assigned to one of two groups; patients in the probiotic group received a daily capsule containing 10⁸ colony forming units (CFUs) of Lactobacillus casei 01 (L. casei 01), while those in the placebo group took identical capsules containing maltodextrin, for 8 weeks. In the baseline and at the end of the study, anxiety, physical activity levels, and dietary intakes were assessed. Anthropometric parameters, serum malondialdehyde (MDA), total antioxidant capacity (TAC), erythrocyte superoxide dismutase (SOD), glutathione peroxidase (GPx), and catalase (CAT) activities were measured.

Results: There was no significant difference between the two groups for demographic characteristics, anthropometric parameters, physical activity, anxiety levels, or dietary intakes, throughout the course of the study. No significant within- and between-group differences were observed for MDA, TAC, or CAT. SOD activity decreased only in the probiotic group and GPx activity decreased in both study groups (p < 0.05); however, no significant between-group difference was found for these enzymes activities at the end of the study (p > 0.05).

Conclusion: No significant effect of L. casei 01 supplementation was observed on the oxidative status of patients with RA, compared to placebo.     

Turmeric Supplementation Improves Serum Glucose Indices and Leptin Levels in Patients with Nonalcoholic Fatty Liver Diseases

Objective: Insulin and leptin resistance are important risk factors for non-alcoholic fatty liver disease (NAFLD). There is limited evidence regarding the effects of turmeric on NAFLD. The aim of this study was to investigate the effects of turmeric supplementation on glycemic status and serum leptin levels in patients with NAFLD.

Methods: This double-blind randomized controlled clinical trial was conducted on 46 patients with NAFLD (21males and 25 females) aged 20–60 years old and body mass index (BMI) between 24.9 and 40 kg/m2. The turmeric group (n = 23) was given six turmeric capsules daily for 12 weeks. Each capsule contained 500 mg turmeric powder (6×500 mg). The placebo group (n = 23) was given six placebo capsules daily for the same period. Fasting blood samples, anthropometric measurements, and physical activity levels were collected at the baseline and at the end of the study. Daily dietary intakes also were obtained throughout the study. Data were analyzed by independent t test, paired t test and analysis of covariance.

Results: Turmeric consumption decreased serum levels of glucose, insulin, HOMA-IR and leptin (by 1.22, 17.69, 19.48 and 21.33% respectively, p < 0.05 for all) over 12 weeks compared with those variables in the placebo group. Changes in weight, BMI and liver enzymes were not significant compared to the placebo group.

Conclusions: Turmeric supplementation improved glucose indexes and serum leptin levels and may be useful in the control of NAFLD complications.     

非酒精性脂肪肝患者血清瘦素水平与肝纤维化关系研究

目的研究瘦素与非酒精性脂肪肝（NAFL）肝纤维化发生与发展的关系。方法用ELISA方法测定30例NAFL患者血清瘦素水平,20例健康人作为对照组,同时检测NAFL患者的血清肝纤维化指标HA、LN、pcⅢ,对血清瘦素与肝纤维化指标的关系进行分析。结果NAFL患者血清瘦素水平明显高于对照组,轻、中、重度非酒精性脂肪肝患者血清瘦素水平依次增高．差异有显著性（p〈0．05）;中、重度非酒精性脂肪肝患者血清瘦素水平与肝纤维化血清学指标呈正相关。结论瘦素在NAFL发病中具有独立的致病作用,并可能是NAFL肝纤维化形成中重要的调控因子之一。     

非酒精性脂肪肝患者血清瘦素水平与肝纤维化关系研究

目的研究瘦素与非酒精性脂肪肝(NAFL)肝纤维化发生与发展的关系。方法用ELISA方法测定30例NAFL患者血清瘦素水平,20例健康人作为对照组,同时检测NAFL患者的血清肝纤维化指标HA、LN、PCⅢ,对血清瘦素与肝纤维化指标的关系进行分析。结果NAFL患者血清瘦素水平明显高于对照组,轻、中、重度非酒精性脂肪肝患者血清瘦素水平依次增高,差异有显著性(p<0.05);中、重度非酒精性脂肪肝患者血清瘦素水平与肝纤维化血清学指标呈正相关。结论瘦素在NAFL发病中具有独立的致病作用,并可能是NAFL肝纤维化形成中重要的调控因子之一。     

非酒精性脂肪性肝病糖代谢异常与血清脂连素关系研究

目的探讨非酒精性脂肪性肝病(NAFLD)患者糖代谢与血清脂联素关系。方法选择2010年10月至2011年11月我院140例门诊确诊的非酒精性脂肪肝病患者,根据糖耐量结果,分为糖耐量正常组及糖代谢异常组,并选择50例健康体检者为对照组,测定所有体检者的IBM、血清谷丙转氨酶(ALT)水平,应用酶联免疫吸附法(ELISA)测定血清中脂联素含量。结果①NAFLD患者糖代谢异常的发生率高达55.7%。②NAFLD患者血清脂连素水平均低于健康对照组,其中合并糖代谢异常者下降更明显,肝功能损伤也更严重。结论血清脂联素水平、糖代谢异常与NAFLD发生、发展密切相关。OGTT及血清脂联素检测,有望作为临床评估NAFLD程度及判断预后的一项指标。     

非酒精性脂肪肝与糖脂代谢异常的关系

目的探讨非酒精性脂肪肝（NAFLD）与糖脂代谢异常的关系。方法以3647名NAFLD患者与同时参加体检的6338名非脂肪肝健康体检者（对照组）的糖脂代谢相关指标进行统计分析。结果9985名企业退休人员体检检出NAFLD3647名，患病率为36．5％。NAFLD组的体重、体重指数（BMI）、收缩压（SBP）、舒张压（DBP）、胆固醇（TC）、甘油三酯（TG）、谷丙转氩酶（ALT）、空腹血糖（FBS）均高于对照组，差异有统计学意义。NAFLD组中高甘油三酯血症、高胆固醇血症、混合性高脂血症、超重、肥胖、空腹血糖受损、糖尿病的患病率均高于对照组。将NAFLD的可能危险因素进行logistic回归分析，相关性由高到低依次为：BMI（OR=1．785，P=0．000）、TG（OR=1．712，P=0．000）、FBS（OR=1．157，P=0．000）、TC（OR=1．138，P=0．005）、身高（OR=1．105，P=0．005）、ALT（OR：1.013，P=0．000）、DBP（OR=1．008，P=0．031）与NAFLD相关，而促甲状腺索（TSH）未能进人模型（P=0．631）。结论企业退休人员NAFLD的患病率高，NAFLD与糖脂代谢的多项指标相关，而TSH与NAFLD无显著相关。     

茵栀黄联合二甲双胍治疗非酒精性脂肪肝病临床疗效及对患者血糖、血脂和氧化应激水平的影响

目的探讨茵栀黄联合二甲双胍治疗非酒精性脂肪肝病(NAFLD)的临床疗效及对患者血糖、血脂和氧化应激水平的影响。方法对我院2015年1月至2017年6月收治的96例NAFLD患者的临床资料进行回顾性分析,根据治疗方式不同将其分为研究组、对照组(各48例),对照组在常规治疗的基础上采用单纯二甲双胍治疗,研究组在常规治疗的基础上采用茵栀黄注射液联合二甲双胍治疗。比较两组治疗疗效及治疗前后丙氨酸氨基转移酶(ALT)、天冬氨酸氨基转移酶(AST)、血清甘油三酯(TG)、总胆固醇(TC)、高密度脂蛋白(HDL-C)、低密度脂蛋白(LDL-C)、空腹血糖(FPG)、餐后2 h血糖(2hPG)、超氧化物歧化酶(SOD)、丙二醛(MDA)及Irisin指标水平。结果研究组治疗总有效率(89.58%)明显高于对照组(70.83%),P<0.05;两组患者治疗前ALT、AST、FPG、2hPG、Irisin、TG、TC、HDL-C、LDL-C、SOD、MDA水平比较均无差异(P>0.05);治疗后两组患者ALT、AST、FPG、2hPG、Irisin、TG、TC、LDL-C、MDA水平均较治疗前下降,且研究组较对照组下降更明显(P<0.05);HDL-C、SOD均较治疗前上升,且研究组较对照组上升更明显(P<0.05)。结论茵栀黄联合二甲双胍治疗NAFLD临床疗效显著,还可有效地改善患者肝功能及血糖、血脂代谢,并具有一定的抗氧化应激作用。     

Whey Protein Supplementation Improves the Glycemic Response and May Reduce Non-Alcoholic Fatty Liver Disease Related Biomarkers in Women with Polycystic Ovary Syndrome (PCOS)

Polycystic ovary syndrome (PCOS) increases type 2 diabetes and non-alcoholic fatty liver disease (NAFLD) with insulin resistance. We hypothesized that a 35 g whey preload would improve insulin sensitivity and glucose handling while reducing biomarkers associated with NAFLD. Twenty-nine age-matched women (CON = 15, PCOS = 14) completed oral glycemic tolerance tests following baseline (Day 0) as well as an acute (Day 1) and short-term whey supplementation (Day 7). Whey had an interaction effect on glucose (p = 0.02) and insulin (p = 0.03), with glucose remaining stable and insulin increasing with whey supplementation. Insulin sensitivity (p < 0.01) improved with whey associated with increased glucagon secretion (p < 0.01). Alanine aminotransferase (ALT), and aspartate aminotransferase (AST) remained unchanged, but “day” had an effect on the AST:ALT ratio (p = 0.04), whereas triglycerides and sex hormone binding globulin overall were greater in the PCOS group (p < 0.05). Total cholesterol decreased in PCOS (by 13%) and CON (by 8%) (NS). HepG2 cells treated with plasma from participants before and after whey decreased lipid accumulation in the PCOS group after whey (p < 0.05). Whey provided an insulinogenic and glycemic homeostatic effect in women with PCOS with the potential to combat NAFLD-consequences.     

130例非酒精性脂肪肝患者临床分析

目的：了解非酒精性脂肪肝患者的临床特点。方法：分析130例非酒精性脂肪肝（NAFLD组）患者和50例健康对照者（对照组）的临床资料,包括身高、年龄、性别、体质量、腰围、血压、空腹血糖（FPG）、甘油三酯（TG）、总胆固醇（TC）、谷丙转氨酶（ALT）、尿酸（UA）、高密度脂蛋白（HDL-C）及低密度脂蛋白（LDL-C）等。结果：NAFLD患者高发年龄在40-60岁之间,女性随年龄增长发病率逐渐升高。NAFLD患者体质量、体质量指数、腰围、血压、FPG、TG、LDL-C、ALT、UA水平均明显高于对照组,而HDL-C水平明显低于对照组,差异均有统计学意义（P〈0.05）。结论：及早进行临床生化和超声检查,同时改变不良生活方式,可以有效预防NAFLD的发生发展。     

Omega-7 Mixed Fatty Acid Supplementation Fails to Reduce Serum Inflammatory Biomarkers: A Placebo-Controlled,Double-Blind Randomized Crossover Trial

We report the effects of mixed omega-7 fatty acid supplementation on changes in serum hsCRP, TNFα, and IL-6 levels and self-reported outcomes in people with non-specific chronic musculoskeletal discomfort. Design: A double-blind, placebo-controlled, 1:1 randomized single crossover trial composed of 688 mg/day palmiteolate for the verum and an equivalent amount of medium-chain triglycerides for the placebo. Method: Data were analyzed in two independent groups and as a crossover group. Results: From 211 screened participants in 2017–2019, 56 were randomized. Six participants dropped out and fifty completers contributed to the statistical analyses. At baseline, none of the investigated biomarkers were significantly correlated to subjectively assessed musculoskeletal discomfort levels. For the two-group analysis (n = 26 and n = 24), none of the serum biomarkers reached statistical significance; however, a statistically significant placebo effect was found in the subjective outcomes. Conclusion: For the crossover analysis (n = 50), three weeks of supplementation with n7FA containing 688 mg per day of palmiteolate did not reduce serum inflammatory biomarkers nor did it improve subjectively measured quality of life (QoL) compared to placebo. Future studies should explore appropriate biomarkers, sufficient power, length of dosing, inclusion criteria for volunteers with higher BMI, and the verification of cis-palmiteolate versus trans-palmiteolate.     

Examining the Relationship Between Nonalcoholic Fatty Liver Disease and the Metabolic Syndrome in Nondiabetic Subjects

Objective: Nonalcoholic fatty liver disease (NAFLD) is considered by some to be the hepatic manifestation of the metabolic syndrome (MS). However, others believe NAFLD is a distinct entity that actually initiates MS. Whichever is true, a definite linkage exists between both is generally accepted based upon the frequency of common occurrence and realization that insulin resistance (IR) is and realization that. The objective is to better understand the relationship between NAFLD and MS. Specifically, is there any concrete evidence that development of NAFLD precedes MS or vice versa? Another goal was to better comprehend capabilities of circulating aminotransferases (aspartate aminotransferase [AST] and alanine aminotransferase [ALT]) and their ratio used commonly for diagnosis of NAFLD.

Methods: Data from 288 participants with fasting blood glucose (FBG) levels below the diabetic level (<125 mg/dL) and AST and ALT values in the normal range (<40 U/L) were examined. Correlations between ALT and AST and their ratio as independent variables with a variety of metabolic parameter were evaluated and compared.

Results: Like FBG, many significant positive correlations among glucose–insulin indices, body composition, blood pressure, dyslipidemias, and inflammation were discovered using ALT, and less so with AST, as the independent variable. In some cases, even stronger correlations in a negative direction with IR and MS were found with the ratio AST/ALT. Corroboration occurred when values in the lowest and highest quartiles of ALT and AST/ALT readings showed appropriate statistically significant differences. Conclusions: The findings here suggest that both NAFLD and the MS very early in development have a common inciting mechanism(s)—most likely IR. Accordingly, the early concurrent temporal results are consistent with the concept that NAFLD is a hepatic manifestation of the IR associated with the MS. They do not exclude the possibility that once some liver functional adjustments take place, several aspects of the MS are bolstered further, perhaps via intensified heightening of IR.     

罗格列酮联合维生素E治疗非酒精性脂肪性肝病的临床研究

目的：探讨罗格列酮联合维生素E治疗非酒精性脂肪性肝病（NAFLD）的临床疗效。方法：将本院进行饮食控制和适当锻炼的90例NAFLD患者随机分为三组,每组30例,分别应用罗格列酮、维生素E、罗格列酮联合维生素E三种方法治疗,疗程为6个月。比较治疗前后各组肝功能指标（ALT、AST、GGT）、血脂水平（TG）、NAFLD超声形态学的改善情况。结果：治疗后三组肝功能、血脂较治疗前均有所改善（P〈0.05）,其中肝功能（ALT、AST、GGT）改善尤为明显（P〈0.01）。治疗后三组肝功能、血脂比较差异均有统计学意义（P〈0.01）,联合组治疗后肝功能（ALT、AST、GGT）改善优于维生素E组及罗格列酮组（P〈0.01）,TG改善亦优于其他两组（P〈0.05）。维生素E组、罗格列酮组、联合组有效率分别为53.33%,66.67%,90.00%;联合组与罗格列酮组、维生素E组比较,差异均有统计学意义（字2=4.812,P〈0.05;字2=9.932,P〈0.01）。结论：罗格列酮和维生素E联合治疗NAFLD安全有效,且联合治疗的效果要优于单药治疗。     

肝炎后非酒精性脂肪肝的膳食营养干预

目的观察营养干预对肝炎后非酒精性脂肪肝(NAFL)的改善。方法52例肝炎后NAFL患者随机分为观察组(n=29)和对照组(n=23),两组给予相同的药物治疗,观察组另给予为期6个月的营养干预,对照组则自主选择食物。结果观察组经营养干预后人体各项测量值,天冬氨酸转移酶、丙氨酸转移酶、甘油三脂、血糖和胆固醇、低密度脂蛋白水平明显低于对照组(P<0.05～0.01),高密度脂蛋白较对照组明显上升(P<0.05),而总胆红素的水平两组间差异无显著性。B超结果显示,观察组干预后有17例患者脂肪肝得到改善,两组相比差异有显著性(P<0.01)。结论合理的营养干预可以稳定肝炎病情,并使患者脂肪肝得到改善。